コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 ith glioblastoma underwent T1Gd, T2, and 18F-FMISO-11 studies preceded surgical resection or biopsy,
2 8F-FMISO images were scaled to the blood 18F-FMISO activity to create tumor-to-blood ratio (T/B) imag
3 that the distribution of hypoxia seen on 18F-FMISO is correlated spatially and quantitatively with th
7 Fluorine 18-labeled fluoromisonidazole ([18F]FMISO), a PET tracer that undergoes irreversible selecti
15 oxygen dependency of binding similar to [18F]FMISO in vitro and displaying less retention in liver an
16 tudy included 10 patients who underwent [18F]FMISO and 15O PET within 1 to 8 days of severe or modera
21 roducibility of the visual analyses of (18)F-FMISO and (18)F-FLT PET/CT images was demonstrated using
28 animals, using the hypoxic cell tracer (18)F-FMISO and the reporter substrate (124)I-FIAU, yielded si
32 1/k2, and k3-surrogates for perfusion, (18)F-FMISO distribution volume, and hypoxia-mediated entrapme
34 cancer patients underwent 0- to 30-min (18)F-FMISO dPET in a customized immobilization mask, followed
37 udy, pharmacokinetic analysis (PKA) of (18)F-FMISO dynamic PET extended to 3 h after injection is rep
39 zole was coadministered with the first (18)F-FMISO injection, and 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2
43 resulted in a marked reduction in the (18)F-FMISO mean standardized uptake value (SUV(mean)) in appr
46 r), CT (of the anatomy), and late-time (18)F-FMISO PET (of the T/B) and parametric images of K(i) (po
49 a in inflammation using (18)F-FAZA and (18)F-FMISO PET imaging represents a promising new tool for un
53 the present study, static and dynamic (18)F-FMISO PET were performed with mice bearing either U87MG
60 ignificant reduction of mean voxelwise (18)F-FMISO TBR, K1, and K1/k2 in both the 2-d and the 7-d gro
61 re analyzed, the observed reduction in (18)F-FMISO uptake after treatment with cediranib may be mista
62 clarify the ambiguity in interpreting (18)F-FMISO uptake and improve the characterization of lesions
63 discrepancy between k3 maps and total (18)F-FMISO uptake and reducing the dynamic range of total (18
64 y an overlap analysis of the volume of (18)F-FMISO uptake and the volumes of the high CBV regions and
72 moral distributions of (124)I-FIAU and (18)F-FMISO were similar, and eGFP, pimonidazole, EF5, and CA9
73 oxia tracers (18)F-fluoromisonidazole ((18)F-FMISO) and (18)F-fluoroazomycinarabinoside ((18)F-FAZA).
75 s of (18)F-labeled fluoromisonidazole ((18)F-FMISO) dynamic PET to assist the identification of regio
77 assessed by (18)F-fluoromisonidazole ((18)F-FMISO) PET and conventional and perfusion MRI before sur
78 s to evaluate (18)F-fluromisonidazole ((18)F-FMISO) PET for monitoring the tumor response to the anti
80 with dynamic (18)F-fluoromisonidazole ((18)F-FMISO) PET may allow for an improved response assessment
81 s with significant (18)F-misonidazole ((18)F-FMISO) uptake in patients with non-small cell lung carci
82 ((18)F-FDG), (18)F-fluoromisonidazole ((18)F-FMISO), and 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT
84 ectively, 0.59 for (18)F-FDG, 0.43 for (18)F-FMISO, and 0.44 for (18)F-FLT using the 5-level scale; t
86 the HT29-9HRE xenograft: (124)I-FIAU, (18)F-FMISO, Hoechst (perfusion), lectin-TRITC (functional blo
91 ncluded, 54 were included, and 34 were (18)F-FMISO-positive, 24 of whom received escalated doses of u
92 adiotracers ((18)F-fluoromisonidazole [(18)F-FMISO], (18)F-flortanidazole [(18)F-HX4], (18)F-fluoroaz
93 ((18)F-FDG, (18)F-fluoromisonidazole [(18)F-FMISO], and (18)F-fluoride) in preclinical mouse models
95 ns of [18F]FETA and [18F]fluoromisonidazole (FMISO) at 2 and 4 h postinjection in C3H mice bearing KH
96 lar proliferation, (18)F-fluoromisonidazole (FMISO) for tissue hypoxia, and (11)C-verapamil for P-gly
97 reoperatively with (18)F-fluoromisonidazole (FMISO)-PET and serial gadolinium-enhanced T1- and T2-wei
99 ined tumor volume, and the mean intensity on FMISO-PET scaled to the blood activity of the tracer (me
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。